The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia. (August 2016)

• Record Type: Journal Article
• Authors: Matuszak, Magdalena; Lewandowski, Krzysztof; Czyż, Anna; Kiernicka-Parulska, Jolanta; Przybyłowicz-Chalecka, Anna; Jarmuż-Szymczak, Małgorzata; Lewandowska, Maria; Komarnicki, Mieczysław
• Is Part Of: Leukemia research. Volume 47(2016:Aug.)
• Page Start: 166
• Page End: 171
• Publication Date: 2016-08
• Subjects: B-cell chronic lymphocytic leukemia -- Dipetydylpeptidase IV/CD26 -- Prognostic factors; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2016.06.002
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: CD26 expression correlates with Rai's clinical stage at diagnosis, β2-microglobulin concentration, LDH activity and ALC. In B-CLL patients TTT is significantly and independently influenced by clinical disease stage according to Rai, LDH activity and CD26 expression on B-CLL cells. CD26 expression correlates with Rai's stage, β2-microglobulin, LDH and ALC. CD26 expression does not correlate with patient's gender, age and CD38 expression. TTT is significantly influenced by Rai's stage, LDH activity and CD26 expression. Abstract: A number of factors related to B-cell chronic lymphocytic leukemia (B-CLL) patients' prognosis have been identified. However, still some factors better reflecting disease activity in individual cases are explored. The study aimed to evaluate prognostic significance of dipeptidylpeptidase IV/CD26 expression on B-CLL cells and its relationship with other well established prognostic factors. The study included 94 patients with newly diagnosed B-CLL and involved analysis of clinical, laboratory, flow-cytometry and cytogenetic data. Detailed analysis showed that CD26 expression on B-CLL cells correlates with Rai's clinical stage of the disease at diagnosis (p = 0.034), β2-microglobulin concentration (p = 0.012), lactic acid dehydrogenase activity (p = 0.045) and absolute lymphocytes' count (p = 0.027) in the blood. The multivariate analysis revealed that time to treatment (TTT) was significantly influenced by Rai clinical stage, LDH activity in blood and CD26 expression on B-CLL cell's. Moreover, in the multivariate analysis restricted to the group of patients with documented cytogenetic risk (n = 36) CD26 expression, Rai clinical stage and cytogenetic profile remained their independent impact on TTT. The results of our study indicate that the CD26 expression should be incorporated in B-CLL patients risk assessment along with well known prognostic factors, since it seems to have a relationship with the tumor mass and influences TTT.